

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-112023-000471

Date: 19th December 2023

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. How many patients were treated in October 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

Q2. How many patients were treated in October 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

Response

The latest available months data (November 2023) has been provided.

Q1. In November 2023, the following number of patients were issued with the listed drugs by the Dermatology department:

Treatment	PT Count
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	0
Dupilumab (Dupixent)	31
Omalizumab (Xolair)	0
Tralokinumab (Adtralza)	1
Upadacitinib (Rinvoq)	10

Q2. In November 2023, the following number of patients were issued with the listed drugs by the Respiratory Medicine department:

Treatment	PT Count
Benralizumab (Fasenra)	40
Dupilumab (Dupixent)	7
Mepolizumab (Nucala)	48
Omalizumab (Xolair)	23
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	7

**Please note that these figures represent the number of PTs issued a new stock of the listed medicine in Nov23, however some of these medicines are ordered on a lower than monthly basis (e.g. every 8 weeks). Since only 1 month of data (Nov23) was requested, there may be some PTs who were being treated in Nov23 but are not counted in these figures because they were issued a new stock of medicine earlier (e.g., in Oct23)*

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell’s Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust